Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | IL1B | P01584 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23956997 | 1.00 | NR1H2 (0.41) | NR1H2GPR119JAK1USP30IL1B | |
| SCHEMBL25625907 | 1.00 | NR1H2 (0.41) | NR1H2GPR119JAK1USP30IL1B | |
| SCHEMBL30367657 | 0.94 | NR1H2 (0.41) | NR1H2GPR119JAK1USP30HDAC1 | |
| SCHEMBL30367419 | 0.92 | NR1H2 (0.43) | NR1H2GPR119JAK1USP30HDAC1 | |
| SCHEMBL29919449 | 0.86 | NR1H2 (0.46) | NR1H2GPR119JAK1USP30HDAC1 | |
| SCHEMBL24575390 | 0.86 | NR1H2 (0.46) | NR1H2GPR119JAK1USP30HDAC1 | |
| SCHEMBL23933511 | 0.85 | GRIN2B (0.39) | JAK1IL1BGRIN2BJAK2 | |
| SCHEMBL23933508 | 0.85 | GRIN2B (0.39) | JAK1IL1BGRIN2BJAK2 | |
| SCHEMBL23933514 | 0.85 | GRIN2B (0.39) | JAK1IL1BGRIN2BJAK2 | |
| SCHEMBL24575034 | 0.85 | NR1H2 (0.40) | NR1H2GPR119JAK1USP30HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | NR1H2 498/4885GPR119 119/4885JAK1 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.